PRC
RARE icon

Pearl River Capital’s Ultragenyx Pharmaceutical RARE Stock Holding History

Pearl River Capital’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-7,671
Closed -$315K – 297
2024
Q2 		$315K Buy
+7,671
New +$328K 0.05% 353
2021
Q2 		– Sell
-2,422
Closed -$276K – 546
2021
Q1 		$276K Sell
2,422
-922
-28% -$126K 0.09% 306
2020
Q4 		$463K Sell
3,344
-2,488
-43% -$295K 0.17% 195
2020
Q3 		$479K Buy
+5,832
New +$483K 0.2% 173
2020
Q2 		– Sell
-888
Closed -$39K – 521
2020
Q1 		$39K Buy
+888
New +$46.1K 0.08% 268
2019
Q1 		– Sell
-319
Closed -$14K – 696
2018
Q4 		$14K Buy
+319
New +$17.4K 0.06% 424

Other funds holding RARE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Pearl River Capital's RARE Position: Q3 2024 in Review

Pearl River Capital sold out of Ultragenyx Pharmaceutical (RARE) in Q3 2024, closing a stake of 7,671 shares — an estimated $315K sold.

Pearl River Capital first reported a position in RARE in Q4 2018 and held it in 6 quarters. The position peaked at $479K in Q3 2020. 300 funds tracked by Wall St. Rank hold RARE as of Q3 2024.

  • Pearl River Capital reported no remaining Ultragenyx Pharmaceutical position as of Q3 2024 after selling out during the quarter.
  • Pearl River Capital sold 7,671 Ultragenyx Pharmaceutical shares in Q3 2024, an estimated $315K.
  • Pearl River Capital first reported a position in Ultragenyx Pharmaceutical in Q4 2018 and held it in 6 quarters.
  • Pearl River Capital's Ultragenyx Pharmaceutical position peaked at $479K in Q3 2020.
  • 300 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2024.

Based on Pearl River Capital's 13F filing for Q3 2024.